Our RESETTM clinical trials with rese-cel (investigational CD19-CAR T cell therapy) in lupus, myositis, systemic sclerosis, myasthenia gravis, and pemphigus vulgaris are now recruiting.
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 04/17/26 | PRE 14A | Preliminary proxy statement not related to a contested matter or merger/acquisition |
|
  |
67 |
| 03/23/26 | S-8 | Securities to be offered to employees in employee benefit plans |
|
|
16 |
| 03/23/26 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] |
|
|
221 |
| 03/23/26 | 8-K | Current report |
|
|
57 |
| 03/02/26 | 4 | Statement of changes in beneficial ownership of securities |
|
1 | |
| 03/02/26 | 4 | Statement of changes in beneficial ownership of securities |
|
1 | |
| 03/02/26 | 4 | Statement of changes in beneficial ownership of securities |
|
1 | |
| 03/02/26 | 4 | Statement of changes in beneficial ownership of securities |
|
1 | |
| 03/02/26 | 4 | Statement of changes in beneficial ownership of securities |
|
1 | |
| 03/02/26 | 4 | Statement of changes in beneficial ownership of securities |
|
1 |
